Cargando…
Splicing therapeutics for Alzheimer's disease
The earliest clinical manifestation of Alzheimer's disease (AD) is cognitive impairment caused by synaptic dysfunction. ApoE4, the primary risk factor for late‐onset AD, disrupts synaptic homeostasis by impairing synaptic ApoE receptor trafficking. Alternative splicing of ApoE receptor‐2 (Apoer...
Autores principales: | Wasser, Catherine R, Herz, Joachim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818748/ https://www.ncbi.nlm.nih.gov/pubmed/26902203 http://dx.doi.org/10.15252/emmm.201506067 |
Ejemplares similares
-
Potential terahertz therapeutic strategy for the prevention or mitigation of Alzheimer’s disease pathology
por: Wang, Xinke, et al.
Publicado: (2023) -
CLK2 blockade modulates alternative splicing compromising MYC‐driven breast tumors
por: Salvador, Fernando, et al.
Publicado: (2018) -
Alternative splicing variability: exactly how similar are two identical cells?
por: Perriman, Rhonda J, et al.
Publicado: (2011) -
Stress-induced tRNA fragments take action in alternative splicing in Arabidopsis
por: Cao, Dechang
Publicado: (2023) -
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease
por: Dobrowolska Zakaria, Justyna A, et al.
Publicado: (2018)